SCHEMBL3681360

SCHEMBL3681360

CCC(C(=O)O)[N+](C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 1/20 0.38
POLB P06746 1/20 0.38
ALPG P10696 1/20 0.38
CHRM1 P11229 1/20 0.36
AKR1A1 P14550 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA2 P00918 1/20 0.36
MAPK1 P28482 1/20 0.36
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6045267 0.97 ALPL (0.36) ALPLPOLBALPGCHRM1AKR1A1
Acetic Acid SCHEMBL3682289 0.95 ALPL (0.35) ALPLPOLBALPGCHRM1AKR1A1
Acetic Acid SCHEMBL3682298 0.91 ALPL (0.41) ALPLPOLBALPGCHRM1AKR1A1
Trifluoroacetic Acid SCHEMBL3684531 0.87 ALPL (0.35) ALPLPOLBALPG
Trifluoroacetic Acid SCHEMBL3684537 0.83 ALPL (0.37) ALPLPOLBALPG
SCHEMBL15610744 0.79 CHRM1 (0.33) ALPLPOLBALPGCHRM1AKR1A1
SCHEMBL5538444 0.79 CHRM1 (0.50) ALPLPOLBALPGCHRM1AKR1A1
SCHEMBL172177 0.78 OR51E2 (0.39) ALPLPOLBALPGSLC1A1GABRR1
SCHEMBL7505468 0.78 OR51E2 (0.39) ALPLPOLBALPGSLC1A1GABRR1
SCHEMBL1427298 0.76 POLB (0.50) ALPLPOLBALPGCA2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4500182-A1 PROGNOSTIC BIOMARKERS The University of Liverpool (GB) 2025-02-05 EP disclosed
WO-2023180753-A1 PROGNOSTIC BIOMARKERS THE UNIVERSITY OF LIVERPOOL (GB) 2023-09-28 WO disclosed
US-9764069-B2 Articles having non-fouling surfaces and processes for preparing the same including pretreatment of articles SEMPRUS BIOSCIENCES CORPORATION (US) 2017-09-19 US disclosed
US-9694114-B2 Antimicrobial catheters with permeabilization agents ARROW INTERNATIONAL, INC. (US) 2017-07-04 US disclosed
US-20160235893-A1 ANTIMICROBIAL CATHETERS WITH PERMEABILIZATION AGENTS JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT 2016-08-18 US disclosed
US-9006359-B2 Imbibing process for contact lens surface modification SEMPRUS BIOSCIENCES CORPORATION (US) 2015-04-14 US disclosed
US-20150045515-A1 NON-FOULING, ANTI-MICROBIAL, ANTI-THROMBOGENIC GRAFT-FROM COMPOSITIONS TELEFLEX LIFE SCIENCES LIMITED (MT) 2015-02-12 US disclosed
US-20140037967-A1 ARTICLES HAVING NON-FOULING SURFACES AND PROCESSES FOR PREPARING THE SAME INCLUDING PRETREATMENT OF ARTICLES SEMPRUS BIOSCIENCES CORPORATION (US) 2014-02-06 US disclosed
CN-103497978-A Preparation method for high-optical-purity L-carnitine BENGBU BBCA MEDICINE SCIENCE & DEV CO LTD 2014-01-08 CN disclosed
US-20130158518-A1 SURFACE MODIFICATION FOR CATHETERS COMPRISED OF MULTIPLE MATERIALS SEMPRUS BIOSCIENCES CORP. (US) 2013-06-20 US disclosed
US-8410150-B2 Inhibitors of carnitine palmitoyltransferase and treating cancer UNIVERSITY HEALTH NETWORK (CA) 2013-04-02 US disclosed
CN-102918015-A Process for hydrochlorination of multihydroxylated aliphatic hydrocarbons DOW GLOBAL TECHNOLOGIES LLC 2013-02-06 CN disclosed
CN-101838212-A Method for synthesizing L-carnitine by using (R)-(-)-3-chlorine-1,2-propylene glycol as chiral initiative raw material UNIV SCIENCE & TECHNOLOGY BEIJING 2010-09-22 CN disclosed
CN-101823974-A Preparation method by adopting (R)-(-)-glycerinchlorohydrin as chirality starting material to synthetize L-carnitine UNIV BEIJING SCIENCE & TECH 2010-09-08 CN disclosed
US-20100105900-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK 2010-04-29 US disclosed
CN-1443574-A Ranzhi Jianfei oral preparation for reducing weight JIANG DIANSHUI (CN) 2003-09-24 CN disclosed
EP-0711768-B1 BENZIMIDAZOLE DERIVATIVE MITSUI CHEMICALS INC (JP) 2002-02-13 EP disclosed
CN-1311787-A oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them ASTRA ZENECA CO LTD (SE) 2001-09-05 CN disclosed
US-5852011-A Benzimidazole derivatives MITSUI CHEMICALS, INC. (JP) 1998-12-22 US disclosed
EP-0711768-A1 BENZIMIDAZOLE DERIVATIVE MITSUI TOATSU CHEMICALS, Inc. (JP) 1996-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105900-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER CPT1A, CPT1B, CPT2 ALPL 2487/4885POLB 1534/4885ALPG 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.